RFK JR. ANNOUNCEMENT · FEB 27 2026 · 14 PEPTIDES RETURN TO CATEGORY 1DATABASE UPDATED · 847 NEW PUBMED CITATIONS THIS WEEKRETATRUTIDE · GRADE B EVIDENCE · 4 NEW CLINICAL TRIALSCOA SCANS · 2,341 BATCHES VERIFIED BY COMMUNITY THIS MONTHFDA ENFORCEMENT · PEPTIDE SCIENCES SHUTDOWN · MAR 2026GLP-1 DIRECTORY · 47 VERIFIED TELEHEALTH CLINICSRFK JR. ANNOUNCEMENT · FEB 27 2026 · 14 PEPTIDES RETURN TO CATEGORY 1DATABASE UPDATED · 847 NEW PUBMED CITATIONS THIS WEEKRETATRUTIDE · GRADE B EVIDENCE · 4 NEW CLINICAL TRIALSCOA SCANS · 2,341 BATCHES VERIFIED BY COMMUNITY THIS MONTHFDA ENFORCEMENT · PEPTIDE SCIENCES SHUTDOWN · MAR 2026GLP-1 DIRECTORY · 47 VERIFIED TELEHEALTH CLINICS
Home/Compounds/CJC-1295
Growth hormoneRx required

CJC-1295

Also known as: CJC-1295 DAC · CJC-1295 no DAC · Modified GRF 1-29

Growth hormone releasing hormone analog with extended half-life for sustained GH elevation.

B
Grade B
Human observational studies
Human studies13
PubMed citations19
Typical dose100 mcg – 2 mg
Routesubcutaneous
Regulatory (US)Compounding legal
Last verifiedyesterday
TL;DR · 30-second summary
  • 2-10x increase in GH levels
  • Sustained IGF-1 elevation for 6+ days (DAC version)
  • Synergistic effects when combined with GHRP
  • Improved body composition in studies

Mechanism of action

Synthetic GHRH analog that stimulates pituitary GH release. DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. No-DAC version has ~30 min half-life.

Evidence summary

13
Human studies
19
PubMed citations
0
Clinical trials
B
Evidence grade

Phase 2 trials demonstrate sustained IGF-1 elevation for 6+ days with DAC version. Shown to increase GH levels 2-10x baseline. Generally well-tolerated.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Dose range
100 mcg – 2 mg

No-DAC: 100mcg 2-3x daily. DAC version: 1-2mg once weekly. Often combined with ipamorelin for synergistic effect.

Administration routes
subcutaneous

Side effects & safety

Reported side effects
FlushingHeadacheDizzinessWater retentionInjection site reactions
Contraindications
  • Active cancer
  • Pregnancy
  • Diabetic retinopathy

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Not FDA approved. Available through compounding pharmacies with prescription.

Compounding
Permitted

Available through compounding pharmacies with valid prescription.

Regulatory data last verified 4/17/2026

Citations

PMID 41880199Coutinho LFD, DE Oliveira Neves LF et al. · A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.The Journal of sports medicine and physical fitness (2026)PMID 41490200Rahman OF, Lee SJ et al. · Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)HumanPMID 41476424Mayfield CK, Bolia IK et al. · Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.The American journal of sports medicine (2026)HumanPMID 41966639Mendias CL, Awan TM · Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports medicine (Auckland, N.Z.) (2026)HumanPMID 41138283Uçaktürk E, Nemutlu E · Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.Journal of pharmaceutical and biomedical analysis (2025)HumanPMID 38197510Thomas A, Walpurgis K et al. · Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.Journal of mass spectrometry : JMS (2024)HumanPMID 38716080Thomas A, Thilmany S et al. · Probing for peptidic drugs (2-10 kDa) in doping control blood samples.Analytical science advances (2024)HumanPMID 35298973Coppieters G, Deventer K et al. · An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis (2022)PMID 30938069Timms M, Ganio K et al. · A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.Drug testing and analysis (2020)HumanPMID 30489688Timms M, Ganio K et al. · An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.Drug testing and analysis (2019)PMID 30136411Gajda PM, Holm NB et al. · Glycine-modified growth hormone secretagogues identified in seized doping material.Drug testing and analysis (2019)PMID 23318763Kwok WH, Ho EN et al. · Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry.Analytical and bioanalytical chemistry (2013)HumanPMID 21871962Thomas A, Schänzer W et al. · Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.Methods (San Diego, Calif.) (2012)HumanPMID 21204297Henninge J, Pepaj M et al. · Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.Drug testing and analysis (2011)PMID 19386527Sackmann-Sala L, Ding J et al. · Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (2010)HumanPMID 19332789Gautam D, Jeon J et al. · Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth.Proceedings of the National Academy of Sciences of the United States of America (2009)HumanPMID 17018654Ionescu M, Frohman LA · Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism (2007)HumanPMID 16822960Alba M, Fintini D et al. · Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism (2006)PMID 15817669Jetté L, Léger R et al. · Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.Endocrinology (2005)Human